Log in

NASDAQ:TCDATricida Stock Price, Forecast & News

+0.11 (+0.42 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $26.10
50-Day Range
MA: $28.20
52-Week Range
Now: $26.10
Volume477,921 shs
Average Volume503,973 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More
Tricida logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.21 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TCDA



Sales & Book Value

Annual SalesN/A
Book Value$5.32 per share


Net Income$-176,810,000.00


Market Cap$1.30 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

Tricida (NASDAQ:TCDA) Frequently Asked Questions

How has Tricida's stock been impacted by COVID-19 (Coronavirus)?

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 7.0% and is now trading at $26.0950. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tricida?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida.

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($1.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.41) by $0.08. View Tricida's earnings history.

What price target have analysts set for TCDA?

3 brokers have issued 12-month target prices for Tricida's stock. Their forecasts range from $48.00 to $50.00. On average, they expect Tricida's stock price to reach $49.33 in the next year. This suggests a possible upside of 89.1% from the stock's current price. View analysts' price targets for Tricida.

Has Tricida been receiving favorable news coverage?

Media stories about TCDA stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tricida earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutTricida.

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
  • Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
  • Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
  • Steffen Pietzke, VP of Fin. & Chief Accounting Officer
  • Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.51%), BlackRock Inc. (5.48%), Redmile Group LLC (4.26%), JPMorgan Chase & Co. (3.01%), Cormorant Asset Management LP (1.76%) and Vivo Capital LLC (1.05%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View institutional ownership trends for Tricida.

Which major investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Driehaus Capital Management LLC, Cormorant Asset Management LP, Deutsche Bank AG, State Street Corp, International Biotechnology Trust PLC, Morgan Stanley, and Redmile Group LLC. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl. View insider buying and selling activity for Tricida.

Which major investors are buying Tricida stock?

TCDA stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, New York State Common Retirement Fund, Burrage Capital Management LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, and Alyeska Investment Group L.P.. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal, and Steffen Pietzke. View insider buying and selling activity for Tricida.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $26.10.

How big of a company is Tricida?

Tricida has a market capitalization of $1.30 billion. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.